Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
≥Ying Zhang,1 Trong Kim Le,1 James W Shaw,2 Srividya Kotapati31Center for Observational Research and Data Sciences, Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb Research and Development, Hopewell, NJ, USA; 2Worldwide Health Economics and Outcomes Research, Bristol-My...
Main Authors: | Zhang Y, Le TK, Shaw JW, Kotapati S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-07-01
|
Series: | ClinicoEconomics and Outcomes Research |
Online Access: | http://www.dovepress.com/retrospective-analysis-of-drug-utilization-health-care-resource-use-an-peer-reviewed-article-CEOR |
Similar Items
-
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery
by: Krishna A, et al.
Published: (2012-06-01) -
Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients
by: Hribernik Andrejc, et al.
Published: (2016-02-01) -
Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma
by: JIA Dongdong, LI Tao
Published: (2022-12-01) -
Societal preferences for adjuvant melanoma health states: UK and Australia
by: Middleton, M, et al.
Published: (2017) -
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma
by: Hemstock, M, et al.
Published: (2020)